Rapid Technological Advancement to Drive the Automated Microbiology Market

Introduction

Automated microbiology involves the application of advanced technologies in the field of microbiology that enables the delivery of accurate and quick results. The advent of automation in microbiology accelerates the productivity, reliability, and efficiency of microbial testing. Automated microbiology helps in the early detection of various infectious agents such as parasites, viruses, fungi, and bacteria, which can cause several life-threatening diseases such as rubella, Ebola, and influenza, among others.

Increased investments by the governments and leading players for the development of novel products for infectious disease diagnosis drive the market growth. For instance, in 2019, Merck partnered with India’s Food Safety and Standards Authority of India (FSSAI) to integrate automated microbiological testing in food safety. The Center for Microbiological Analysis Training (C-MAT) will offer training programs to food safety scientists in government laboratories and FSSAI-ratified private laboratories on the latest technology in microbiological testing.

The Infectious Diseases Society of America (IDSA) has developed an action plan and policy statement to promote the investment in clinical microbiology in order to increase the adoption of automated resources that provide accurate and fast test results. On July 23, 2018, Cepheid, an American diagnostic company, reduced its Xpert tests price to USD 14, used for microbial testing of a human immunodeficiency virus (HIV), viral hepatitis (HCV), and human papillomavirus (HPV).

Key Highlights

• The automated microbiology market was valued at USD 4,494.6 million in 2019 and is projected to grow with a CAGR of 9.18% on account of rising incidences of infectious diseases and technological advancement in microbiology.
• The reagents segment holds the largest market share owing to the repeated purchase driven by the increasing need for a new set of reagents and surging demand for microbial research activities.
• The automated culture systems segment is projected to grow at a significant rate due to its increasing adoption in various microbiological laboratories to perform cell biology, cell signaling, and drug discovery, and protein expression.
• The hospital laboratories segment accounted for the largest market share
• North America dominates the market owing to the high use of advanced technology and a strong presence of leading market players.

Competitive Players

1. Becton Dickinson and Company
2. Microbiology International
3. Thermo Fisher Scientific, Inc.
4. bioMérieux, Inc.
5. Cardinal Health
6. Beckman Coulter, Inc.
7. Merck KGaA
8. Rapid Micro Biosystems, Inc.
9. Clever Culture Systems
10. Zhuhai Meihua Medical Technology Ltd.

Recent Developments

• November 2023- London Health Sciences Centre (LHSC) and St. Joseph's Heath Care London (St. Joseph's) unveiled the installation of a Total Laboratory Automation (TLA) system within the clinical microbiology laboratory. The TLA system is the first of its kind to be installed in the world, making London an international flagship site for innovation in clinical microbiology.
• January 2024- Samsung Biologics selected Rapid Micro Biosystems' Growth Direct platform to automate crucial microbiology quality control tests. Rapid Micro Biosystems, Inc., an innovative life sciences technology company that provides mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced that Samsung Biologics has chosen the Growth Direct® platform to automate its microbial quality control processes, resulting in increased efficiency, stronger data integrity, and scalable quality control operations.

Segmentation

1. By Product
   1. Instruments
   2. Automated Culture Systems
   3. Microbiology Analyzers
   4. Reagents
2. By Deployment
   1. DNA and RNA Probe Technology
   2. DNA sequencing
   3. Detection Techniques
   4. Non-Isotopic Methods
   5. Immunoassays
   6. Monoclonal Antibodies
   7. Radioactive Methods
3. By End-User
   1. Clinical Laboratories
   2. Biotechnology Industries
   3. Others